LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

Search

TG Therapeutics Inc

Avatud

SektorTervishoid

37.72 1.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.18

Max

37.97

Põhinäitajad

By Trading Economics

Sissetulek

-18M

5.1M

Müük

13M

121M

P/E

Sektori keskmine

144.08

50.291

Aktsiakasum

0.03

Kasumimarginaal

4.187

Töötajad

352

EBITDA

-20M

12M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.62% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

947M

5.7B

Eelmine avamishind

36.32

Eelmine sulgemishind

37.72

Uudiste sentiment

By Acuity

50%

50%

154 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

TG Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. aug 2024, 20:01 UTC

Tulu

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Võrdlus sarnastega

Hinnamuutus

TG Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

9.62% tõus

12 kuu keskmine prognoos

Keskmine 41.6 USD  9.62%

Kõrge 55 USD

Madal 11 USD

Põhineb 5 Wall Streeti analüütiku instrumendi TG Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

4

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

N/A / 34.86Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

154 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.